Impact of genetics on the clinical management of channelopathies

Peter J. Schwartz, Michael John Ackerman, Alfred L. George, Arthur A M Wilde

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

There are few areas in cardiology in which the impact of genetics and genetic testing on clinical management has been as great as in cardiac channelopathies, arrhythmic disorders of genetic origin related to the ionic control of the cardiac action potential. Among the growing number of diseases identified as channelopathies, 3 are sufficiently prevalent to represent significant clinical and societal problems and to warrant adequate understanding by practicing cardiologists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome. This review will focus selectively on the impact of genetic discoveries on clinical management of these 3 diseases. For each disorder, we will discuss to what extent genetic knowledge and clinical genetic test results modify the way cardiologists should approach and manage affected patients. We will also address the optimal use of genetic testing, including its potential limitations and the potential medico-legal implications when such testing is not performed. We will highlight how important it is to understand the ways that genotype can affect clinical manifestations, risk stratification, and responses to the therapy. We will also illustrate the close bridge between molecular biology and clinical medicine, and will emphasize that consideration of the genetic basis for these heritable arrhythmia syndromes and the proper use and interpretation of clinical genetic testing should remain the standard of care.

Original languageEnglish (US)
Pages (from-to)169-180
Number of pages12
JournalJournal of the American College of Cardiology
Volume62
Issue number3
DOIs
StatePublished - Jul 16 2013

Fingerprint

Channelopathies
Genetic Testing
Brugada Syndrome
Molecular Medicine
Long QT Syndrome
Inborn Genetic Diseases
Clinical Medicine
Standard of Care
Disease Management
Cardiology
Action Potentials
Cardiac Arrhythmias
Molecular Biology
Genotype
Cardiologists
Therapeutics

Keywords

  • channelopathies
  • gene-specific management
  • genetic testing
  • heart rhythm disorder
  • sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of genetics on the clinical management of channelopathies. / Schwartz, Peter J.; Ackerman, Michael John; George, Alfred L.; Wilde, Arthur A M.

In: Journal of the American College of Cardiology, Vol. 62, No. 3, 16.07.2013, p. 169-180.

Research output: Contribution to journalArticle

Schwartz, Peter J. ; Ackerman, Michael John ; George, Alfred L. ; Wilde, Arthur A M. / Impact of genetics on the clinical management of channelopathies. In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 3. pp. 169-180.
@article{848ed3254c4a4901accc4fa4340c43e8,
title = "Impact of genetics on the clinical management of channelopathies",
abstract = "There are few areas in cardiology in which the impact of genetics and genetic testing on clinical management has been as great as in cardiac channelopathies, arrhythmic disorders of genetic origin related to the ionic control of the cardiac action potential. Among the growing number of diseases identified as channelopathies, 3 are sufficiently prevalent to represent significant clinical and societal problems and to warrant adequate understanding by practicing cardiologists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome. This review will focus selectively on the impact of genetic discoveries on clinical management of these 3 diseases. For each disorder, we will discuss to what extent genetic knowledge and clinical genetic test results modify the way cardiologists should approach and manage affected patients. We will also address the optimal use of genetic testing, including its potential limitations and the potential medico-legal implications when such testing is not performed. We will highlight how important it is to understand the ways that genotype can affect clinical manifestations, risk stratification, and responses to the therapy. We will also illustrate the close bridge between molecular biology and clinical medicine, and will emphasize that consideration of the genetic basis for these heritable arrhythmia syndromes and the proper use and interpretation of clinical genetic testing should remain the standard of care.",
keywords = "channelopathies, gene-specific management, genetic testing, heart rhythm disorder, sudden death",
author = "Schwartz, {Peter J.} and Ackerman, {Michael John} and George, {Alfred L.} and Wilde, {Arthur A M}",
year = "2013",
month = "7",
day = "16",
doi = "10.1016/j.jacc.2013.04.044",
language = "English (US)",
volume = "62",
pages = "169--180",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Impact of genetics on the clinical management of channelopathies

AU - Schwartz, Peter J.

AU - Ackerman, Michael John

AU - George, Alfred L.

AU - Wilde, Arthur A M

PY - 2013/7/16

Y1 - 2013/7/16

N2 - There are few areas in cardiology in which the impact of genetics and genetic testing on clinical management has been as great as in cardiac channelopathies, arrhythmic disorders of genetic origin related to the ionic control of the cardiac action potential. Among the growing number of diseases identified as channelopathies, 3 are sufficiently prevalent to represent significant clinical and societal problems and to warrant adequate understanding by practicing cardiologists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome. This review will focus selectively on the impact of genetic discoveries on clinical management of these 3 diseases. For each disorder, we will discuss to what extent genetic knowledge and clinical genetic test results modify the way cardiologists should approach and manage affected patients. We will also address the optimal use of genetic testing, including its potential limitations and the potential medico-legal implications when such testing is not performed. We will highlight how important it is to understand the ways that genotype can affect clinical manifestations, risk stratification, and responses to the therapy. We will also illustrate the close bridge between molecular biology and clinical medicine, and will emphasize that consideration of the genetic basis for these heritable arrhythmia syndromes and the proper use and interpretation of clinical genetic testing should remain the standard of care.

AB - There are few areas in cardiology in which the impact of genetics and genetic testing on clinical management has been as great as in cardiac channelopathies, arrhythmic disorders of genetic origin related to the ionic control of the cardiac action potential. Among the growing number of diseases identified as channelopathies, 3 are sufficiently prevalent to represent significant clinical and societal problems and to warrant adequate understanding by practicing cardiologists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome. This review will focus selectively on the impact of genetic discoveries on clinical management of these 3 diseases. For each disorder, we will discuss to what extent genetic knowledge and clinical genetic test results modify the way cardiologists should approach and manage affected patients. We will also address the optimal use of genetic testing, including its potential limitations and the potential medico-legal implications when such testing is not performed. We will highlight how important it is to understand the ways that genotype can affect clinical manifestations, risk stratification, and responses to the therapy. We will also illustrate the close bridge between molecular biology and clinical medicine, and will emphasize that consideration of the genetic basis for these heritable arrhythmia syndromes and the proper use and interpretation of clinical genetic testing should remain the standard of care.

KW - channelopathies

KW - gene-specific management

KW - genetic testing

KW - heart rhythm disorder

KW - sudden death

UR - http://www.scopus.com/inward/record.url?scp=84880078317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880078317&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.04.044

DO - 10.1016/j.jacc.2013.04.044

M3 - Article

C2 - 23684683

AN - SCOPUS:84880078317

VL - 62

SP - 169

EP - 180

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 3

ER -